Moderna faces vaccine vs. therapy naming dilemma

Moderna is grappling with a significant naming challenge, caught between the established term "vaccine" and the more nuanced "individualized neoantigen treatment." This dilemma, reminiscent of historical naming paradoxes, stems from vaccine skepticism that emerged during the Trump era. The company's ambitious plans for next-generation mRNA vaccines targeting influenza and novel pathogens are reportedly hindered by this semantic debate. The choice of terminology could impact public perception and regulatory pathways for their innovative medical solutions.